Kathleen A.  Rickard net worth and biography

Kathleen Rickard Biography and Net Worth

Insider of Verona Pharma
Dr Rickard has more than 25 years of experience in clinical research in respiratory medicine, industry, and management. Prior to joining Verona Pharma, Dr Rickard served in multiple roles at Aerocrine and subsequently Circassia, where she was instrumental in directing clinical and regulatory strategies for NIOX VERO, an airway inflammation test for managing asthma, across key markets such as the US, China, and Japan, as well as the rest of the world. Previously, Dr Rickard was Vice President Clinical Development and Medical Affairs of GlaxoSmithKline’s Respiratory Medicines Development Centre and, over a period of 15 years, held a number of other leadership positions in clinical development across GlaxoSmithKline’s global respiratory franchise. Dr Rickard received an MD from Hahnemann University Hospital, Philadelphia.

What is Kathleen A. Rickard's net worth?

The estimated net worth of Kathleen A. Rickard is at least $38.32 million as of November 3rd, 2023. Dr. Rickard owns 2,840,640 shares of Verona Pharma stock worth more than $38,320,234 as of December 6th. This net worth approximation does not reflect any other assets that Dr. Rickard may own. Additionally, Dr. Rickard receives an annual salary of $655,000.00 as Insider at Verona Pharma. Learn More about Kathleen A. Rickard's net worth.

How old is Kathleen A. Rickard?

Dr. Rickard is currently 65 years old. There are 5 older executives and no younger executives at Verona Pharma. Learn More on Kathleen A. Rickard's age.

What is Kathleen A. Rickard's salary?

As the Insider of Verona Pharma plc, Dr. Rickard earns $655,000.00 per year. There are 2 executives that earn more than Dr. Rickard. The highest earning executive at Verona Pharma is Dr. David S. Zaccardelli, President, CEO & Executive Director, who commands a salary of $1,050,000.00 per year. Learn More on Kathleen A. Rickard's salary.

How do I contact Kathleen A. Rickard?

The corporate mailing address for Dr. Rickard and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Kathleen A. Rickard's contact information.

Has Kathleen A. Rickard been buying or selling shares of Verona Pharma?

In the last ninety days, Kathleen A. Rickard has sold $112,803.84 in shares of Verona Pharma stock. Most recently, Kathleen A. Rickard sold 58,752 shares of the business's stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $1.92, for a transaction totalling $112,803.84. Following the completion of the sale, the insider now directly owns 2,840,640 shares of the company's stock, valued at $5,454,028.80. Learn More on Kathleen A. Rickard's trading history.

Who are Verona Pharma's active insiders?

Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.

Are insiders buying or selling shares of Verona Pharma?

In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 26 times. They sold a total of 8,061,833 shares worth more than $104,534,812.64. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 3.9% of the company. Learn More about insider trades at Verona Pharma.

Information on this page was last updated on 11/20/2023.

Kathleen A. Rickard Insider Trading History at Verona Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2023Sell58,752$1.92$112,803.842,840,640View SEC Filing Icon  
8/7/2023Sell1,600$2.47$3,952.002,872,528View SEC Filing Icon  
8/3/2023Sell50,600$2.55$129,030.002,902,072View SEC Filing Icon  
8/1/2023Sell19,736$2.68$52,892.482,966,400View SEC Filing Icon  
5/3/2023Sell28,752$2.65$76,192.802,971,136View SEC Filing Icon  
5/1/2023Sell77,424$2.58$199,753.922,999,888View SEC Filing Icon  
2/1/2023Sell89,960$2.56$230,297.603,106,064View SEC Filing Icon  
8/2/2022Sell28,752$0.70$20,126.402,376,040View SEC Filing Icon  
5/3/2022Sell28,752$0.49$14,088.482,461,224View SEC Filing Icon  
4/11/2022Sell59,720$0.54$32,248.802,546,408View SEC Filing Icon  
4/8/2022Sell112,800$0.59$66,552.002,606,128View SEC Filing Icon  
See Full Table

Kathleen A. Rickard Buying and Selling Activity at Verona Pharma

This chart shows Kathleen A Rickard's buying and selling at Verona Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma Company Overview

Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $13.61
Low: $13.43
High: $13.84

50 Day Range

MA: $14.17
Low: $11.94
High: $16.94

2 Week Range

Now: $13.61
Low: $11.77
High: $26.44


130,326 shs

Average Volume

454,462 shs

Market Capitalization

$8.65 billion

P/E Ratio


Dividend Yield